Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTS: Almonertinib in Resected Stage II-IIIB EGFR-mutant NSCLC
NCT04687241Phase 3Active, not recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Apr 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Almonertinib Arm with Placebo Arm (2 arms). Primary endpoint: Disease Free Survival assessed by Independent Review Committee at 4 years. Started Apr 2021; status: active, not recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04687241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04687241.